Second Fosamax Bellwether Case Ends In Unanimous Verdict For Defendant Merck

NEW YORK — (Mealey’s) The second federal Fosamax bellwether trial ended in a defense verdict May 6 when a jury in the U.S. District Court for the Southern District of New York unanimously found that the plaintiff did not suffer from osteonecrosis of the jaw (ONJ) as of March 31, 2004, a date...

Jury Awards Plaintiff $8 Million In Fosamax Lawsuit

NEW YORK - (Mealey's) A jury returned an $8 million compensatory damages verdict against Merck & Co. Inc. on June 25 in the U.S. District Court for the Southern District of New York in the retrial of the first Fosamax multidistrict litigation case to go to trial, according to the court's...

$8M Fosamax Verdict Remitted By MDL Judge To $1.5M Or New Damages Trial

NEW YORK -- (Mealey's) The New York federal judge overseeing the Fosamax multidistrict litigation on Oct. 4 sua sponte found that an $8 million verdict in a bellwether trial is excessive and ordered a remittitur of the verdict to $1.5 million unless plaintiff Shirley Boles wants a new trial on damages...

N.J. Jury Finds Novartis Didn't Fail To Warn About Jaw Risk From Aredia, Zometa Bone Drugs

NEW BRUNSWICK, N.J. -- A New Jersey state court jury on Oct. 6 found that Novartis Pharmaceuticals Corp. did not fail to provide adequate warning to a cancer patient's doctor that its bone-saving drugs Aredia and Zometa had a risk of osteonecrosis of the jaw (ONJ) ( Jane Bessemer v. Novartis Pharmaceuticals...

2nd Fosamax Bellwether Plaintiff Failed To Prove Causation, 2nd Circuit Affirms

NEW YORK - (Mealey's) The second bellwether plaintiff in the Fosamax multidistrict litigation failed to produce evidence that the osteoporosis drug caused her osteonecrosis of the jaw (ONJ), a panel of the Second Circuit U.S. Court of Appeals ruled Nov. 5 in affirming summary judgment ( Bessie L...

Novartis Wins Defense Verdict In Zometa Jaw Injury Trial

BROOKLYN, N.Y. (Mealey's) A New York federal jury in the first federal Zometa trial found May 25 that the plaintiff did not prove by a preponderance of evidence that the Novartis Pharmaceuticals Corp. drug caused a decedent's osteonecrosis of the jaw (ONJ) ( Karlene Hogan, et al. v. Novartis...

Fosamax MDL Jury: Drug Wasn't Defectively Designed, Didn't Cause Jaw Injury

NEW YORK - A New York federal jury hearing the fourth Fosamax bellwether trial on Oct. 3 found that Merck's osteoporosis drug was not defectively designed and did not cause a plaintiff to develop osteonecrosis of the jaw (ONJ) ( In Re: Fosamax Products Liability Litigation , MDL Docket No. 1789,...

Jury Awards Plaintiff $10.4 Million For Injuries, Punitive Damages Linked To Novartis' Zometa

CENTRAL ISLIP, N.Y. - (Mealey's) A New York federal jury on Nov. 2 found Novartis Pharmaceuticals Corp. liable for a woman's osteonecrosis of the jaw (ONJ) and awarded her $10.45 million, according to the parties ( Barbara Davids v. Novartis Pharmaceuticals Corporation , No. 2:06-431, E.D. N...

Jury Awards Plaintiff $285,000 In 5th Fosamax MDL Trial But Finds No Design Defect

NEW YORK - (Mealey's) A New York federal jury on Feb. 5 ordered Novartis Pharmaceuticals Corp. to pay $285,000 to a plaintiff for allegedly failing to warn her or her doctor that Fosamax carries a risk of osteonecrosis of the jaw (ONJ) ( In Re: Fosamax Products Liability Litigation , MDL Docket No...

N.J. Jury Finds For Defendant Novartis In Zometa Jaw Injury Trial

NEW BRUNSWICK, N.J. - (Mealey's) A New Jersey state court jury on May 15 returned a defense verdict for Novartis Pharmaceuticals Corp. in a Zometa jaw injury case, a source told Mealey Publications ( Beverly Meng v. Novartis Pharmaceuticals Corp. , No. MID-L-7670-07-MT, N.J. Super., Middlesex Co...

Jury Awards $1.3 Million In Zometa Jaw Injury Trial After Botching 1st Verdict Form

ORLANDO, Fla. — (Mealey’s) A Florida federal jury on Sept. 20 found that Novartis Pharmaceuticals Corp. failed to warn a cancer patient about the risk of osteonecrosis of the jaw (ONJ) and awarded her $1.3 million in medical expenses and non-economic damages ( Nancy Guenther, et al. v. Novartis...

Merck To Settle Suits Alleging Jaw Damage From Osteoporosis Drug

WHITEHOUSE STATION, N.J. — (Mealey's) Merck & Co. Inc. has agreed to pay $27.7 million to resolve product liability suits alleging that its osteoporosis drug Fosamax caused osteonecrosis of the jaw (ONJ), or bone death, according to a press release the company issued Dec. 9 ( In Re: Fosamax...